Multiple myeloma is a cancer of the bone marrow, with a life expectancy of less than 5 years post-diagnosis. Proteasome inhibitors, the therapeutic backbone of current treatments, are very effective in treating newly diagnosed ...
Jan 12, 2022
0
18
A drug that strips cancer cells of their quest for immortality represents an effective new option for patients with Waldenström macroglobulinemia, including those not helped by the only class of drugs currently approved ...
Nov 19, 2021
0
3
Proteasome inhibitors have significant promise as components of novel combination therapies to treat multidrug-resistant malaria, according to a study published June 6 in the open-access journal PLOS Pathogens by David Fidock, ...
Jun 6, 2019
0
5
(HealthDay)—For patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor has failed, progression-free survival (PFS) is longer in those receiving the immunostimulatory monoclonal antibody ...
Nov 8, 2018
0
0
The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy comes with the ...
Dec 28, 2017
0
6
A new class of drugs for blood cancers such as leukemia and multiple myeloma is showing promise. But it is hobbled by a problem that also plagues other cancer drugs: targeted cells can develop resistance. Now scientists, ...
Oct 25, 2017
0
1
Some of the most promising new treatments for blood cancers, drugs called proteasome inhibitors, have a problem: For reasons that researchers are still working to fully understand, cancer cells can build up a resistance to ...
Oct 25, 2017
0
0
Maintaining appropriate levels of proteins within cells largely relies on a cellular component called the proteasome, which degrades unneeded or defective proteins to recycle the components for the eventual assembly of new ...
Aug 16, 2016
0
194
De Bruin carries out chemical-biological research on proteasomes. 'They are a kind of degradation factory that cuts proteins in cells into smaller fragments. It's a highly useful activity: it's a way for cells to clean up ...
May 31, 2016
0
5
A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome ...
Apr 28, 2016
0
1
